TP53 and neoplasm: In our study, we observed a trend that the majority of models experiencing tumor regression greater than KRASG12C inhibitor monotherapy in response to the combination had co-mutation of TP53 and KRASG12C (NCI-H2030, NCI-H1792, NCI-H2122, SW837, SW1463, MIA PaCa-2, ST4859, and ST6365), whereas the inherently resistant models (SW1573 and CR2528) were TP53 WT (Supplementary Table S2).